최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국식품위생안전성학회지 = Journal of food hygiene and safety, v.31 no.1, 2016년, pp.59 - 66
박선미 (고려대학교 생명과학대학 생명공학부 대사공학연구실) , 문현석 (고려대학교 생명과학대학 생명공학부 대사공학연구실)
It has been generally accepted that obesity and overweight are associated with metabolic diseases and cancer incidence. In fact, obesity increased risks of cancers i.e. breast, liver, pancreatic and prostate. Celastrol is a pentacyclic triterpenoid isolated from Thunder god vine, was used as a Chine...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
Celastrol의 구조는 무엇인가? | 10) 이 외에도 동물 실험을 통하여 관절염, 홍반성 낭창, 알츠하이머 및 천식과 같은 질병 치료 효능이 밝혀 졌다.11-13) Celastrol은 triterpene 구조를 가지고 있으며, 이 구조로 인하여 췌장암,14) 전립선암,15) 유방암16) 및 신경 교종17)을 포함한 다양한 암세포의 세포성장을 저해할 뿐만 아니라, 암의 개시, 발전 및 전이를 억제시킨다.15) 최근 논문에 따르면 식욕억제 호르몬인 렙틴(leptin)을 크게 활성 시키는 역할을 하고, 비만 쥐에 투여시 독성없이 체중이 45%나 줄었다는 보고가 있다. | |
Celastrol이란 무엇인가? | 따라서 인체에 이미 사용하여 본 경험이 있는 생약제를 대상으로 현대과학적으로 항암성 활성을 구명하는 것이 매우 의의가 있다. Celastrol은 한방에서는 뇌공등(雷公藤)이라고 하며, 노박덩굴과에 속하는 미역줄나무(Tripterygium wilfordii)의 뿌리에서 추출한 것이다.8) Celastrol은 300년 전부터 관절염, 염증반응 및 자가면역 질병을 치료하기 위하여 쓰여져 오고 있으며, 9) 화학예방, 신경보호작용 및 항산화와 같은 다양한 생리활성 특성을 가지고 있다. | |
celastrol이 활성화시키는 식용억제 호르몬은 무엇인가? | 11-13) Celastrol은 triterpene 구조를 가지고 있으며, 이 구조로 인하여 췌장암,14) 전립선암,15) 유방암16) 및 신경 교종17)을 포함한 다양한 암세포의 세포성장을 저해할 뿐만 아니라, 암의 개시, 발전 및 전이를 억제시킨다.15) 최근 논문에 따르면 식욕억제 호르몬인 렙틴(leptin)을 크게 활성 시키는 역할을 하고, 비만 쥐에 투여시 독성없이 체중이 45%나 줄었다는 보고가 있다.18) 이 결과는 celastrol이 항비만 효과를 가지고 있으며 또한, 비만으로 연계되는 암의 발생과 밀접한 관련성이 있음을 나타낸다. |
Johnson, R.J., Nakagawa, T., Sanchez-Lozada, L.G., Shafiu, M., Sundaram, S., Le, M., Ishimoto, T., Sautin, Y.Y. & Lanaspa, M.A. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes, 62, 3307-3315 (2013).
Nimptsch, K. & Pischon, T. Body fatness, related biomarkers and cancer risk: an epidemiological perspective. Hormone molecular biology and clinical investigation, 22, 39-51 (2015).
Aguilar Cordero, M.J., Gonzalez Jimenez, E., Garcia Lopez, A.P., Alvarez Ferre, J., Padilla Lopez, C.A., Guisado Barrilao, R. & Rizo Baeza, M. [Obesity and its implication in breast cancer]. Nutricion hospitalaria, 26, 899-903 (2011).
Olivo-Marston, S.E., Hursting, S.D., Perkins, S.N., Schetter, A., Khan, M., Croce, C., Harris, C.C. & Lavigne, J. Effects of calorie restriction and diet-induced obesity on murine colon carcinogenesis, growth and inflammatory factors, and microRNA expression. PloS one, 9, e94765 (2014).
Popovic, M.D., Banicevic, A.C., Popovic, B., Ceric, A., Banicevic, A. & Popadic, D. Treatment of endometrial cancer in patient with malignant obesity. Medical archives, 68, 69-70 (2014).
Sanfilippo, K.M., McTigue, K.M., Fidler, C.J., Neaton, J.D., Chang, Y., Fried, L.F., Liu, S. & Kuller, L.H. Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women. Hypertension, 63, 934-941 (2014).
Preziosi, G., Oben, J.A. & Fusai, G. Obesity and pancreatic cancer. Surgical oncology, 23, 61-71 (2014).
Yang, H., Chen, D., Cui, Q.C., Yuan, X. & Dou, Q.P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer research, 66, 4758-4765 (2006).
Salminen, A., Lehtonen, M., Paimela, T. & Kaarniranta, K. Celastrol: Molecular targets of Thunder God Vine. Biochemical and biophysical research communications, 394, 439-442 (2010).
Kim, D.H., Shin, E.K., Kim, Y.H., Lee, B.W., Jun, J.G., Park, J.H. & Kim, J.K. Suppression of inflammatory responses by celastrol, a quinone methide triterpenoid isolated from Celastrus regelii. European journal of clinical investigation, 39, 819-827 (2009).
Tao, X., Younger, J., Fan, F.Z., Wang, B. & Lipsky, P.E. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis and rheumatism, 46, 1735-1743 (2002).
Shrivastava, S., Jeengar, M.K., Reddy, V.S., Reddy, G.B. & Naidu, V.G. Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. Experimental and molecular pathology, 98, 313-327 (2015).
Kannaiyan, R., Shanmugam, M.K. & Sethi, G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer letters, 303, 9-20 (2011).
Yadav, V.R., Sung, B., Prasad, S., Kannappan, R., Cho, S.G., Liu, M., Chaturvedi, M.M. & Aggarwal, B.B. Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. Journal of molecular medicine, 88, 1243-1253 (2010).
Dai, Y., Desano, J., Tang, W., Meng, X., Meng, Y., Burstein, E., Lawrence, T.S. & Xu, L. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PloS one, 5, e14153 (2010).
Kim, Y., Kang, H., Jang, S.W. & Ko, J. Celastrol inhibits breast cancer cell invasion via suppression of NF- ${\kappa}B$ -mediated matrix metalloproteinase-9 expression. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 28, 175-184 (2011).
Li, H.Y., Zhang, J., Sun, L.L., Li, B.H., Gao, H.L., Xie, T., Zhang, N. & Ye, Z.M. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study. Cell death & disease, 6, e1604 (2015).
Greenhill, C. Celastrol identified as a leptin sensitizer and potential novel treatment for obesity. Nature reviews. Endocrinology, 11, 444 (2015).
Woods, R.W., Sisney, G.S., Salkowski, L.R., Shinki, K., Lin, Y. & Burnside, E.S. The mammographic density of a mass is a significant predictor of breast cancer. Radiology, 258, 417- 425 (2011).
van de Ven, S., Smit, V.T., Dekker, T.J., Nortier, J.W. & Kroep, J.R. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer treatment reviews, 37, 422-430 (2011).
Park, Y.J., Ryu, J.W Chemosensitivity test in human breast cancer. Journal of The Korean Surgical Society, 62, 26-29 (2002).
Lee, J.H., Koo, T.H., Yoon, H., Jung, H.S., Jin, H.Z., Lee, K., Hong, Y.S. & Lee, J.J. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochemical pharmacology, 72, 1311- 1321 (2006).
Kim, J.H., Lee, J.O., Lee, S.K., Kim, N., You, G.Y., Moon, J.W., Sha, J., Kim, S.J., Park, S.H. & Kim, H.S. Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway. Cellular signalling, 25, 805-813 (2013).
Baldi, A., De Luca, A., Esposito, V., Campioni, M., Spugnini, E.P. & Citro, G. Tumor suppressors and cell-cycle proteins in lung cancer. Pathology research international, 2011, 605042 (2011).
Yang, H.S., Kim, J.Y., Lee, J.H., Lee, B.W., Park, K.H., Shim, K.H., Lee, M.K. & Seo, K.I. Celastrol isolated from Tripterygium regelii induces apoptosis through both caspasedependent and -independent pathways in human breast cancer cells. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 49, 527-532 (2011).
Adams, J.M. Ways of dying: multiple pathways to apoptosis. Genes & development, 17, 2481-2495 (2003).
Woessner, J.F., Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 5, 2145-2154 (1991).
Scorilas, A., Karameris, A., Arnogiannaki, N., Ardavanis, A., Bassilopoulos, P., Trangas, T. & Talieri, M. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. British journal of cancer, 84, 1488-1496 (2001).
Mi, C., Shi, H., Ma, J., Han, L.Z., Lee, J.J. & Jin, X. Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9. Oncology reports, 32, 2527-2532 (2014).
Key, T., Appleby, P., Barnes, I., Reeves, G., Endogenous, H. & Breast Cancer Collaborative, G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute, 94, 606-616 (2002).
Katzenellenbogen, B.S. & Katzenellenbogen, J.A. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast cancer research : BCR, 2, 335-344 (2000).
Liedtke, C., Broglio, K., Moulder, S., Hsu, L., Kau, S.W., Symmans, W.F., Albarracin, C., Meric-Bernstam, F., Woodward, W., Theriault, R.L., Kiesel, L., Hortobagyi, G.N., Pusztai, L. & Gonzalez-Angulo, A.M. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 20, 1953-1958 (2009).
Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F. & Group, N.C.-N.B.C. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocrine-related cancer, 12, 721-747 (2005).
Carpizo, D.R. & D'Angelica, M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. The Lancet. Oncology, 10, 801-809 (2009).
Yau, T., Chan, P., Epstein, R. & Poon, R.T. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver international : official journal of the International Association for the Study of the Liver, 29, 10-17 (2009).
Tanaka, M., Katayama, F., Kato, H., Tanaka, H., Wang, J., Qiao, Y.L. & Inoue, M. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. Journal of epidemiology / Japan Epidemiological Association, 21, 401-416 (2011).
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. & Forman, D. Global cancer statistics. CA: a cancer journal for clinicians, 61, 69-90 (2011).
Li, P.P., He, W., Yuan, P.F., Song, S.S., Lu, J.T. & Wei, W. Celastrol induces mitochondria-mediated apoptosis in hepatocellular carcinoma Bel-7402 cells. The American journal of Chinese medicine, 43, 137-148 (2015).
Kannaiyan, R., Manu, K.A., Chen, L., Li, F., Rajendran, P., Subramaniam, A., Lam, P., Kumar, A.P. & Sethi, G. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis : an international journal on programmed cell death, 16, 1028-1041 (2011).
Jiang, H.L., Jin, J.Z., Wu, D., Xu, D., Lin, G.F., Yu, H., Ma, D.Y. & Liang, J. Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. Molecular biology reports, 40, 4203-4209 (2013).
Ihle, J.N. STATs: signal transducers and activators of transcription. Cell, 84, 331-334 (1996).
Yue, P. & Turkson, J. Targeting STAT3 in cancer: how successful are we? Expert opinion on investigational drugs, 18, 45-56 (2009).
Rajendran, P., Li, F., Shanmugam, M.K., Kannaiyan, R., Goh, J.N., Wong, K.F., Wang, W., Khin, E., Tergaonkar, V., Kumar, A.P., Luk, J.M. & Sethi, G. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer prevention research, 5, 631- 643 (2012).
Varfolomeev, E.E. & Ashkenazi, A. Tumor necrosis factor: an apoptosis JuNKie? Cell, 116, 491-497 (2004).
Johnson, G.L. & Nakamura, K. The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochimica et biophysica acta, 1773, 1341-1348 (2007).
Ma, J., Han, L.Z., Liang, H., Mi, C., Shi, H., Lee, J.J. & Jin, X. Celastrol inhibits the HIF-1alpha pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells. Oncology reports, 32, 235-242 (2014).
Khan, M.L., Halfdanarson, T.R. & Borad, M.J. Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. Future oncology, 10, 1255-1275 (2014).
Shimoda, M., Katoh, M., Kita, J., Sawada, T. & Kubota, K. The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy, 56, 501-506 (2010).
Xia, Q.S., Ishigaki, Y., Zhao, X., Shimasaki, T., Nakajima, H., Nakagawa, H., Takegami, T., Chen, Z.H. & Motoo, Y. Human SMG-1 is involved in gemcitabine-induced primary microRNA-155/BIC up-regulation in human pancreatic cancer PANC-1 cells. Pancreas, 40, 55-60 (2011).
Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends in molecular medicine, 8, S55-61 (2002).
Kamal, A., Boehm, M.F. & Burrows, F.J. Therapeutic and diagnostic implications of Hsp90 activation. Trends in molecular medicine, 10, 283-290 (2004).
Zhang, T., Hamza, A., Cao, X., Wang, B., Yu, S., Zhan, C.G. & Sun, D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Molecular cancer therapeutics, 7, 162-170 (2008).
Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., Barrera, J.L., Mohar, A., Verastegui, E. & Zlotnik, A. Involvement of chemokine receptors in breast cancer metastasis. Nature, 410, 50-56 (2001).
Marchese, A. & Benovic, J.L. Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting. The Journal of biological chemistry, 276, 45509-45512 (2001).
Bhandari, D., Trejo, J., Benovic, J.L. & Marchese, A. Arrestin- 2 interacts with the ubiquitin-protein isopeptide ligase atrophin-interacting protein 4 and mediates endosomal sorting of the chemokine receptor CXCR4. The Journal of biological chemistry, 282, 36971-36979 (2007).
Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA: a cancer journal for clinicians, 62, 10-29 (2012).
Lee, G.H., Park, J. A., Kim, B. R., Cinn. Y. W., Yoon, C. Y., Yoon, D.K Polymorphism of Androgen Receptor in Korean Men with Prostate Cancer. Korean Urological Association, 6, 561-564 (2005).
Han, M., Partin, A.W., Pound, C.R., Epstein, J.I. & Walsh, P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. The Urologic clinics of North America, 28, 555-565 (2001).
D'Amico, A.V., Cote, K., Loffredo, M., Renshaw, A.A. & Schultz, D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20, 4567-4573 (2002).
Cao, L., Zhang, X., Cao, F., Wang, Y., Shen, Y., Yang, C., Uzan, G., Peng, B. & Zhang, D. Inhibiting inducible miR-223 further reduces viable cells in human cancer cell lines MCF- 7 and PC3 treated by celastrol. BMC cancer, 15, 873 (2015).
Guo, J., Huang, X., Wang, H. & Yang, H. Celastrol Induces Autophagy by Targeting AR/miR-101 in Prostate Cancer Cells. PloS one, 10, e0140745 (2015).
Shao, L., Zhou, Z., Cai, Y., Castro, P., Dakhov, O., Shi, P., Bai, Y., Ji, H., Shen, W. & Wang, J. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-kappaB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer. PloS one, 8, e58391 (2013).
Chiang, K.C., Tsui, K.H., Chung, L.C., Yeh, C.N., Chen, W.T., Chang, P.L. & Juang, H.H. Celastrol blocks interleukin-6 gene expression via downregulation of NF-kappaB in prostate carcinoma cells. PloS one, 9, e93151 (2014).
Ji, N., Li, J., Wei, Z., Kong, F., Jin, H., Chen, X., Li, Y. & Deng, Y. Effect of celastrol on growth inhibition of prostate cancer cells through the regulation of hERG channel in vitro. BioMed research international, 2015, 308475 (2015).
Staudacher, I., Wang, L., Wan, X., Obers, S., Wenzel, W., Tristram, F., Koschny, R., Staudacher, K., Kisselbach, J., Koelsch, P., Schweizer, P.A., Katus, H.A., Ficker, E. & Thomas, D. hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn-Schmiedeberg's archives of pharmacology, 383, 119-139 (2011).
Wolfram, J., Suri, K., Huang, Y., Molinaro, R., Borsoi, C., Scott, B., Boom, K., Paolino, D., Fresta, M., Wang, J., Ferrari, M., Celia, C. & Shen, H. Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells. Journal of microencapsulation, 31, 501-507 (2014).
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.